NAs
Phase 2Small molecule
NAs is one of 101 small molecule programs targeting Cirrhosis. It is currently in Phase 2.
3
Indications
6
Total Trials
6
Active Trials
100
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
75 competitors in Cirrhosis
#DrugCompanyPhaseTrials
1Actos
TakedaApproved
Vemlidy
GileadApproved
Emtriva
GileadApproved
Tyzeka
NovartisApproved
Xifaxan
SSalix
Approved
Esmeron
FFresenius Kabi USA, LLC
Approved
Bridion
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Bumex
VValidus Pharmaceuticals
Phase 3
Crestor
AstraZenecaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chronic Hepatitis b3 trials
Combination Therapy1 trial
Sequential Combination Therapy With PD-1 Antibody and Peg-IFNα in CHB Patients
Recruiting·—·N/A·NCT06457477·50 enrolled
PD-1antibody1 trial
The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients
Active, not recruiting·—·N/A·NCT06357806·45 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NAs. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- AAusper Biopharma Co., Ltd.